T-VEC + Pembrolizumab for Sarcoma

Recruiting in Palo Alto (17 mi)

+4 other locations

Ciara Kelly, MBBCh BAO - MSK Sarcoma ...

Overseen byCiara Kelly, MBBCh BAO

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

The purpose of this study is to determine how well the combination of therapy of talimogene laherparepvec (T-VEC) and pembrolizumab works in the treatment of patients with sarcoma.

Research Team

Ciara Kelly, MBBCh BAO

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

Adults with advanced sarcoma, including specific types like epithelioid and cutaneous angiosarcoma, who have tried at least one systemic therapy or refused standard treatment. Participants must be in good health otherwise, not pregnant or breastfeeding, willing to use contraception, and able to give informed consent.

Inclusion Criteria

Willing to comply with treatment protocol

Women who could become pregnant must have a negative pregnancy test before starting the study.

My cancer is one of the specific types: undifferentiated pleomorphic sarcoma, myxofibrosarcoma, epithelioid sarcoma, or cutaneous angiosarcoma.

See 7 more

Exclusion Criteria

Criterion: You are sensitive to talimogene laherparepvec or pembrolizumab, or have a history of lung disease. You have received certain treatments or surgeries within 21 days before the study starts, are currently in another clinical trial, or have had psychiatric or substance abuse issues.

My brain metastases are stable and haven't progressed in the last 4 weeks.

I do not have a weakened immune system due to conditions like HIV, autoimmune diseases, or recent live vaccines.

See 3 more

Treatment Details

Interventions

Pembrolizumab (Checkpoint Inhibitor)
Talimogene Laherparepvec (T-VEC) (Virus Therapy)

Trial OverviewThe trial is testing a combination of two drugs: T-VEC (Talimogene Laherparepvec) and Pembrolizumab for treating patients with sarcoma. It aims to see how well these drugs work together against this type of cancer.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Talimogene Laherparepvec (T-VEC) Administered with PembrolizuExperimental Treatment2 Interventions

Patients will initiate treatment with talimogene laherparepvec given intralesionally and pembrolizumab.